Pharma major Lupin announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection carried out at its Pithampur Unit -2 (Indore) facility. The inspection was carried out between January 14 and January 25, 2019.
The inspection at Pithampur Unit-2 (Indore) closed with 6 observations. The company is confident of addressing the observations satisfactorily.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
Shares of the company declined Rs 12, or 1.39%, to trade at Rs 851.00. The total volume of shares traded was 0 at the BSE (9.01 a.m., Monday).